AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11297005 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 17
Study 9010695 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg once daily
Number of subjects: 15
Study 9010695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1642682 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble ibuprofen 200 mg sachets
Number of subjects: 0
Study 1642682 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble ibuprofen 400 mg sachets
Number of subjects: 0
Study 1642682 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 200 mg tablets
Number of subjects: 0
Study 1642682 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg tablets
Number of subjects: 0
Study 6503136 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide (1.0 and 2.0 mg)
Number of subjects: 20
Study 6503136 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (40 and 80 mg)
Number of subjects: 20
Study 6503136 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Bumetanide and Furosemide
Number of subjects: 20
Study 30977033 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF 300 mg
Number of subjects: 498
Study 30977033 — intervention group
Group type: COMPARATOR
Intervention: ADV 10 mg
Number of subjects: 498
Study 30100318 — intervention group
Group type: EXPERIMENTAL
Intervention: Thai massage (TM)
Number of subjects: 20
Study 30100318 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish massage (SM)
Number of subjects: 20
Study 27320832 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballistic strength training (3 sessions of 60 minutes per week for 12 weeks) targeting ankle plantarflexors, hip flexors, and hip extensors.
Number of subjects: 166
Study 27320832 — intervention group
Group type: COMPARATOR
Intervention: Usual care (3 sessions of 60 minutes per week for 12 weeks) including balance, strength, stretch, cardiovascular fitness, gait.
Number of subjects: 166
Study 24117487 — intervention group
Group type: EXPERIMENTAL
Intervention: Perhexiline
Number of subjects: 122
Study 22663899 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance‐Free Activity Session (SFAS)
Number of subjects: 82
Study 22663899 — intervention group
Group type: COMPARATOR
Intervention: Relaxation Training (RT)
Number of subjects: 82
Study 19580713 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue spray applied to the axillary fossa in 45 patients
Number of subjects: 90
Study 19580713 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment in 45 patients
Number of subjects: 90
Study 17785082 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-hydroxy-camptothecin (10-HCPT) 10 mg/m2 with 5-fluoro-uracil (5-FU) 425 mg/m2 and leucovorin (LV) 20 mg/m2
Number of subjects: 18
Study 17785082 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-hydroxy-camptothecin (10-HCPT) 12 mg/m2 with 5-fluoro-uracil (5-FU) 425 mg/m2 and leucovorin (LV) 20 mg/m2
Number of subjects: 18
Study 17785082 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-hydroxy-camptothecin (10-HCPT) 14 mg/m2 with 5-fluoro-uracil (5-FU) 425 mg/m2 and leucovorin (LV) 20 mg/m2
Number of subjects: 18
Study 17785082 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-hydroxy-camptothecin (10-HCPT) 8 mg/m2 with 5-fluoro-uracil (5-FU) 425 mg/m2 and leucovorin (LV) 20 mg/m2
Number of subjects: 18
Study 17785082 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-hydroxy-camptothecin (10-HCPT) 4 mg/m2 with 5-fluoro-uracil (5-FU) 425 mg/m2 and leucovorin (LV) 20 mg/m2
Number of subjects: 18
Study 17785082 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-hydroxy-camptothecin (10-HCPT) 6 mg/m2 with 5-fluoro-uracil (5-FU) 425 mg/m2 and leucovorin (LV) 20 mg/m2
Number of subjects: 18
Study 12792005 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained dispensing staff (Family welfare educators and pharmacy technicians)
Number of subjects: 2994
Study 12792005 — intervention group
Group type: EXPERIMENTAL
Intervention: Untrained staff
Number of subjects: 2994
Study 12792005 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesics
Number of subjects: 2994
Study 12792005 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 2994
Study 12792005 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient knowledge assessment
Number of subjects: 2994
Study 11104737 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenously infused nitroglycerin (NTG) for 24 hours
Number of subjects: 0
Study 11104737 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nitrate therapy)
Number of subjects: 0
Study 8729711 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety-related words (stressor)
Number of subjects: 25
Study 8729711 — intervention group
Group type: COMPARATOR
Intervention: Neutral control words
Number of subjects: 25
Study 1735586 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 40 mg/day
Number of subjects: 30
Study 1735586 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 40 mg/day
Number of subjects: 30
Study 6683976 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal absorption from aqueous solution
Number of subjects: 7
Study 6683976 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal absorption from fatty suppository
Number of subjects: 7
Study 6683976 — intervention group
Group type: COMPARATOR
Intervention: Oral dosing of codeine phosphate (60 mg)
Number of subjects: 7
Study 6683976 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal absorption from alkaline solution containing codeine phosphate
Number of subjects: 7
Study 6683976 — intervention group
Group type: EXPERIMENTAL
Intervention: Various rectal dosage forms
Number of subjects: 7
Study 30973437 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature sounds
Number of subjects: 120
Study 30973437 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology massage
Number of subjects: 120
Study 30973437 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature sounds plus foot sole reflexology massage
Number of subjects: 120
Study 30973437 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 28625242 — intervention group
Group type: EXPERIMENTAL
Intervention: miR‐182 in CI group (2.35±0.79)
Number of subjects: 30
Study 28625242 — intervention group
Group type: EXPERIMENTAL
Intervention: Th17% in CI group (5.16±1.89)%
Number of subjects: 30
Study 28625242 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐17 in CI group (37.45±6.20 ng/L)
Number of subjects: 30
Study 28625242 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined miR‐182 and IL‐17
Number of subjects: 30
Study 28625242 — intervention group
Group type: EXPERIMENTAL
Intervention: miR‐182 cut-off value
Number of subjects: 30
Study 28625242 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐17 cut-off value
Number of subjects: 30
Study 26521571 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of acupuncture at head points and seed-pressure at ear points
Number of subjects: 30
Study 26521571 — intervention group
Group type: COMPARATOR
Intervention: Simple acupuncture at head points
Number of subjects: 30
Study 23561971 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatin (Creon(®) 40000 MMS™) at a dose of 80,000 Ph. Eur. lipase units with each of three main meals/day and 40,000 with each of up to three snacks/day
Number of subjects: 61
Study 23561971 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events (TEAEs)
Number of subjects: 61
Study 21613389 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-delivered treatment (CDT)
Number of subjects: 303
Study 21613389 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (ST)
Number of subjects: 303
Study 19892281 — intervention group
Group type: EXPERIMENTAL
Intervention: Banded rapid maxillary expander
Number of subjects: 60
Study 19892281 — intervention group
Group type: COMPARATOR
Intervention: No treatment (NTG)
Number of subjects: 60
Study 16426292 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat petrolatum-based moisturizer
Number of subjects: 644
Study 16426292 — intervention group
Group type: COMPARATOR
Intervention: Protective gloves
Number of subjects: 644
Study 16426292 — intervention group
Group type: EXPERIMENTAL
Intervention: Information and discussions on prevention of skin problems
Number of subjects: 644
Study 16636488 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan
Number of subjects: 500
Study 16636488 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan plus angiotensin converting enzyme (ACE) inhibitor
Number of subjects: 500
Study 16636488 — intervention group
Group type: COMPARATOR
Intervention: valsartan plus ACE inhibitor
Number of subjects: 500
Study 10560360 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 50 mg, twice daily
Number of subjects: 213
Study 10560360 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole 100 mg, twice daily
Number of subjects: 213
Study 8900706 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily condom catheter change
Number of subjects: 113
Study 8900706 — intervention group
Group type: COMPARATOR
Intervention: Every other day condom catheter change
Number of subjects: 113
Study 2069791 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg or 180 mg twice daily
Number of subjects: 34
Study 2069791 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem 240 mg once daily
Number of subjects: 34
Study 2069791 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg twice daily
Number of subjects: 34
Study 2069791 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 180 mg twice daily
Number of subjects: 34
Study 6840169 — intervention group
Group type: EXPERIMENTAL
Intervention: Sobrerol (mucolytic drug)
Number of subjects: 0
Study 6840169 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of serum and urine levels of Sobrerol
Number of subjects: 0
Study 6840169 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass fragmentographic analysis
Number of subjects: 0
Study 31595433 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmic 0.3% gentamicin topical solution nightly for a 3-month period
Number of subjects: 26
Study 31595433 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound cultures of nail plates
Number of subjects: 26
Study 31595433 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatopathology
Number of subjects: 26
Study 31595433 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination findings
Number of subjects: 26
Study 31595433 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermoscopic findings
Number of subjects: 26
Study 30995686 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored tele-monitoring intervention
Number of subjects: 80
Study 30995686 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study 27808005 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT-E), 40 sessions
Number of subjects: 106
Study 27808005 — intervention group
Group type: COMPARATOR
Intervention: Focal Psychodynamic Therapy (FPT), 40 sessions
Number of subjects: 106
Study 27808005 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT-E)
Number of subjects: 106
Study 26479969 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (PCB) plus bare-metal stent (BMS) implantation
Number of subjects: 120
Study 26479969 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS) alone
Number of subjects: 120
Study 24508103 — intervention group
Group type: EXPERIMENTAL
Intervention: vemurafenib (960 mg orally twice daily)
Number of subjects: 675
Study 24508103 — intervention group
Group type: COMPARATOR
Intervention: dacarbazine (1000 mg/m² IV every 3 weeks)
Number of subjects: 675
Study 23204602 — intervention group
Group type: EXPERIMENTAL
Intervention: Active CPAP
Number of subjects: 1098
Study 23204602 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 1098
Study 20920276 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy with capecitabine (825 mg/m² twice daily during radiotherapy)
Number of subjects: 57
Study 20920276 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy with capecitabine
Number of subjects: 57
Study 20920276 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative combined therapy
Number of subjects: 57
Study 18547150 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mL of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 25
Study 18547150 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mL of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 25
Study 18547150 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mL of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 25
Study 18547150 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study 15814754 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mL of ropivacaine 0.5%
Number of subjects: 84
Study 15814754 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of ropivacaine 0.5%
Number of subjects: 84
Study 15814754 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mL of ropivacaine 0.5%
Number of subjects: 84
Study 15814754 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL of ropivacaine 0.5%
Number of subjects: 84
Study 12432177 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CM; 0.3 g kg d 1 + 20 g Polycose)
Number of subjects: 32
Study 12432177 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 32
Study 12432177 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacto‐ovo‐vegetarian diet (LOV)
Number of subjects: 32
Study 12432177 — intervention group
Group type: COMPARATOR
Intervention: Omnivorous diet (Omni)
Number of subjects: 32
Study 10499778 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO (100 U/kg) for 3 months, 3 times per week
Number of subjects: 46
Study 10499778 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO (50% decreased dose) + vitamin E (300 mg/day) for 3 months
Number of subjects: 46
Study 10499778 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (no intervention)
Number of subjects: 46
Study 8613890 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat fiber-supplemented diet (40 g dietary fiber)
Number of subjects: 7
Study 8613890 — intervention group
Group type: COMPARATOR
Intervention: Control diet (15 g dietary fiber)
Number of subjects: 7
Study 1758713 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular transcutaneous electrical nerve stimulation (TENS) at autonomic point
Number of subjects: 24
Study 1758713 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular transcutaneous electrical nerve stimulation (TENS) at wrist point
Number of subjects: 24
Study 1758713 — intervention group
Group type: COMPARATOR
Intervention: Auricular transcutaneous electrical nerve stimulation (TENS) at face point (placebo)
Number of subjects: 24
Study 1758713 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (situation control)
Number of subjects: 24
Study 30851191 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 2629
Study 30851191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2629
Study 28612077 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (5 Hz, 3,000 pulses) applied on the tongue area of the motor cortex for 10 days over 2 weeks
Number of subjects: 15
Study 28612077 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 15
Study 26036554 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (2 mg) via patient-controlled epidural analgesia (PCEA)
Number of subjects: 40
Study 26036554 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) morphine (5 mg) with patient-controlled analgesia (PCA)
Number of subjects: 40
Study 23503736 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training without partial weight support
Number of subjects: 36
Study 23503736 — intervention group
Group type: COMPARATOR
Intervention: Overground walking training on a fixed surface
Number of subjects: 36
Study 21305271 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg/day
Number of subjects: 36
Study 21305271 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg/day
Number of subjects: 36
Study 21305271 — intervention group
Group type: COMPARATOR
Intervention: Normotensive controls
Number of subjects: 36
Study 19667239 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined criteria (Doppler and morphology-based)
Number of subjects: 2170
Study 19667239 — intervention group
Group type: COMPARATOR
Intervention: WHO criteria (exclusively Doppler-based)
Number of subjects: 2170
Study 18091408 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-management (CM) plus usual primary care
Number of subjects: 419
Study 18091408 — intervention group
Group type: COMPARATOR
Intervention: Primary care alone
Number of subjects: 419
Study 15085385 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 405
Study 15085385 — intervention group
Group type: COMPARATOR
Intervention: MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin)
Number of subjects: 405
Study 15085385 — intervention group
Group type: EXPERIMENTAL
Intervention: P-glycoprotein expression
Number of subjects: 405
Study 11346128 — intervention group
Group type: EXPERIMENTAL
Intervention: Day hospital care for 2 months
Number of subjects: 174
Study 11346128 — intervention group
Group type: COMPARATOR
Intervention: Control group (no day hospital care)
Number of subjects: 174
Study 9715842 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (20 mg/m2 every 3 weeks)
Number of subjects: 0
Study 9715842 — intervention group
Group type: COMPARATOR
Intervention: Liposomal daunorubicin (40 mg/m2 every 2 weeks)
Number of subjects: 0
Study 9715842 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Number of subjects: 0
Study 9715842 — intervention group
Group type: COMPARATOR
Intervention: Liposomal daunorubicin
Number of subjects: 0
Study 8021759 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 25
Study 8021759 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 25
Study 8021759 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 25
Study 2657200 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobunolol
Number of subjects: 31
Study 2657200 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol
Number of subjects: 31
Study 31639060 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic analysis using machine‐learning model with selected features and support vector machine classifier
Number of subjects: 239
Study 31639060 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic features selected using the mRMR algorithm
Number of subjects: 239
Study 31639060 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic signature consisting of two first‐order statistics and seven textural features
Number of subjects: 239
Study 29354994 — intervention group
Group type: EXPERIMENTAL
Intervention: Emayaoling acupuncture technique
Number of subjects: 110
Study 29354994 — intervention group
Group type: COMPARATOR
Intervention: Regular acupuncture
Number of subjects: 110
Study 25048999 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol 20% 250mL, albumin 20% 150mL and Ringer's lactate 1,100mL combined with ultrafiltration (group T)
Number of subjects: 134
Study 25048999 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate 1,500mL in the priming reservoir (group C)
Number of subjects: 134
Study 23182307 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation intervention delivered by a hospice-based multidisciplinary team
Number of subjects: 41
Study 23182307 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 41
Study 21564123 — intervention group
Group type: EXPERIMENTAL
Intervention: Red color cue
Number of subjects: 33
Study 21564123 — intervention group
Group type: COMPARATOR
Intervention: Chromatic or achromatic control color
Number of subjects: 33
Study 18359255 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 100
Study 18359255 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical management (CMM)
Number of subjects: 100
Study 16521190 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ-68
Number of subjects: 101
Study 16521190 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 101
Study 12672913 — intervention group
Group type: EXPERIMENTAL
Intervention: High meat diet (20% of energy as protein)
Number of subjects: 15
Study 12672913 — intervention group
Group type: COMPARATOR
Intervention: Low meat diet (12% of energy as protein)
Number of subjects: 15
Study 12672913 — intervention group
Group type: EXPERIMENTAL
Intervention: High meat diet
Number of subjects: 15
Study 12672913 — intervention group
Group type: COMPARATOR
Intervention: Low meat diet
Number of subjects: 15
Study 11099365 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration (0.45% NaCl) equal to 50% of prior dehydration
Number of subjects: 8
Study 11099365 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion (0.45% NaCl) equal to 50% of prior dehydration
Number of subjects: 8
Study 11099365 — intervention group
Group type: COMPARATOR
Intervention: No fluid (NF)
Number of subjects: 8
Study 8607572 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular diet
Number of subjects: 241
Study 8607572 — intervention group
Group type: COMPARATOR
Intervention: Clear liquids
Number of subjects: 241
Study 8659147 — intervention group
Group type: EXPERIMENTAL
Intervention: Burn-prone individuals
Number of subjects: 231
Study 8659147 — intervention group
Group type: COMPARATOR
Intervention: Non-prone individuals
Number of subjects: 231
Study 2908820 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 118,551, 50 mg t.i.d.
Number of subjects: 9
Study 2908820 — intervention group
Group type: COMPARATOR
Intervention: Propranolol, 80 mg t.i.d.
Number of subjects: 9
Study 31444314 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen-containing supplements (gelatin 20 g and hydrolyzed collagen 20 g)
Number of subjects: 0
Study 31444314 — intervention group
Group type: COMPARATOR
Intervention: Dairy protein supplements (calcium caseinate 20 g and hydrolyzed casein 20 g)
Number of subjects: 0